| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1.2K | 12.2% | 12.1% |
| Total Income | 1.2K | 12.0% | 12.1% |
| Expenditure | 1.1K | 9.6% | 12.4% |
| PBT | 111.73 | 70.8% | 9.8% |
| Net Profit | 86.44 | 84.3% | 16.7% |
| OPM | 13.80% | 3.00pp | 0.15pp |
| NPM | 7.28% | 2.86pp | 0.29pp |
| EPS | 5.47 | 84.2% | 16.6% |
Jubilant Ingrevia FY26 Revenue Up 5% YoY, Dividend ₹5/Share
26 May 2026 · 26 May, 2:59 pm
Summary
Jubilant Ingrevia Limited reported a robust performance for Q4 and FY26, with Q4 FY26 revenue growing 12% year-on-year to ₹1,179 crore and EBITDA increasing 11% year-on-year to ₹172 crore. For the full fiscal year, total revenue reached ₹4,388 crore, up 5% from FY25, while Profit After Tax (PAT) grew by 11% to ₹278 crore. The management emphasized strong execution, effective navigation of the Middle East crisis without production loss, and strategic initiatives including the Remidex acquisition and progress on the Agro CDMO facility. The company maintains a bullish outlook for FY27, expecting sustained growth driven by Specialty Chemicals and Nutrition, anticipating sequential revenue and EBITDA growth from Q1 FY27 onwards.
Key Highlights
- 1
Jubilant Ingrevia Limited reported a 12% year-on-year revenue growth, reaching ₹1,179 crore in Q4 FY26.
- 2
EBITDA for Q4 FY26 increased by 11% year-on-year to ₹172 crore, achieving a 15% EBITDA margin.
- 3
For the full fiscal year 2026, total revenue grew by 5% year-on-year to ₹4,388 crore, while EBITDA rose 9% to ₹607 crore.
- 4
Profit after tax (PAT) after exceptional items for FY26 increased by 11% year-on-year to ₹278 crore.
- 5
The Board recommended a final dividend of ₹2.50 per share (250%), bringing the total FY26 dividend to ₹5 per share (500%).
- 6
The company's net debt to EBITDA ratio improved significantly to 0.99x, driven by an 11% reduction in net debt in 2026.
- 7
Key business milestones included the acquisition of Remidex to accelerate the Human Nutrition business and successful dispatch from the newly constructed Agro CDMO facility in Q4 FY26.
Management Comments
Mr. Shyam S Bhartia
We are pleased to report a healthy performance in Q4 and FY26. Our Revenue grew 12% YoY and EBITDA increased 11% YoY in Q4 FY26, reflecting our strong execution. A key highlight for the quarter was our effective handling of the Middle East crisis, with no force majeure and zero production loss. The other highlights include successful dispatch from our newly constructed Agro CDMO facility and the acquisition of Remidex to accelerate the growth of our Human Nutrition business. The Board has recommended a final dividend of ₹2.50 per share (250%), taking total FY26 dividend to ₹5 per share (500%).
Mr. Hari S Bhartia
We are pleased to report a healthy performance in Q4 and FY26. Our Revenue grew 12% YoY and EBITDA increased 11% YoY in Q4 FY26, reflecting our strong execution. A key highlight for the quarter was our effective handling of the Middle East crisis, with no force majeure and zero production loss. The other highlights include successful dispatch from our newly constructed Agro CDMO facility and the acquisition of Remidex to accelerate the growth of our Human Nutrition business. The Board has recommended a final dividend of ₹2.50 per share (250%), taking total FY26 dividend to ₹5 per share (500%).
Mr. Deepak Jain
Over the past year, we have made strong progress across all strategic pillars, building long‑term growth while managing global challenges effectively. Despite Middle East disruptions impacting supply and prices, our diversified sourcing and agility ensured minimal disruption with effective cost pass‑through. Strong customer engagement and timely renegotiations have strengthened resilience, reflected in improved performance in Q4.
Informational and educational content only. Not investment advice.